Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
..yes the Hemp/CBD/MJ Market isn't going away .. ;) glad I have other stocks to be distracted by.. tried to by the other day but was turned away because of the status.. will use my other account soon...
$RLFTF Interesting clip from a yah-oo post :
ARGELIOM4 hours ago
Aviptadil's formulation manufacturing cost appears to be low and long shelf life because it can be freeze-dried and afterwards it can be dehydrated before use. It is perfect for third world countries.
2.1 billion outstanding. 1.22 billion Float.
President DJT was positive on the therapeutics that the FDA are moving along in his call to Fox and friends this morning and was positive on Canada as a supplier...
$RLFTF Relief Ther. and ..they jumped Revive Ther. RVVTF to Pase 3 .. glad I have both ;)
DVR'd it.. busy day.. I'll reply again if I hear anything good.. but the closer we get the better chance we'll be named in the material put in front of him.. IMO
$RVVTF Revive Therapeutics Just Became A Serious Player In The Race To Treat COVID-19
$RVVTF - Revive Therapeutics Just Became A Serious Player In The Race To Treat COVID-19. https://t.co/rF8gcaXEBj #economy #finance #stocks
— Seeking Alpha (@SeekingAlpha) August 5, 2020
$RVVTF Revive Therapeutics Just Became A Serious Player In The Race To Treat COVID-19
$RVVTF - Revive Therapeutics Just Became A Serious Player In The Race To Treat COVID-19. https://t.co/rF8gcaXEBj #economy #finance #stocks
— Seeking Alpha (@SeekingAlpha) August 5, 2020
$RVVTF Mr.Normall (Troll Hunter)6 hours ago
Dr. Boulware Has Advised The White House/Trump
You could say this is... yuge!
https://www.cnn.com/videos/health/2020/05/19/david-boulware-hydroxychloroquine-study-burnett-ebof-intv-vpx.cnn
https://www.globenewswire.com/news-release/2020/03/24/2005654/0/en/Revive-Therapeutics-Appoints-Dr-David-Boulware-MD-as-Scientific-Advisor-for-Infectious-Diseases-including-COVID-19.html
Shouldn't have any trouble with funding, given the connection. One mention on Twitter by DJT and this thing goes parabolic!
New to this.. Q, Does this trade like a stock w/no other fees ? Thanks
..when I went to buy go hit w/a bunch of (high risk) things to sign off on also..
Trump on Fox and friends in the morning talking covid-19...
$RLFTF It's Getting HOT In Here ....
(copy) There is no way 6 patients in severe respiratory failure from covid19 recovered that quickly (AND FOR THE FIRST TIME ON AN ANTIVIRAL) and this stock not explode!
Once the news gets fully absorbed I expect good things. Then again as anticipation builds for the analyzed data later in the month. And there is always a chance that they will halt the study and mark it for widespread use if it is a game changer.
$RLFTF Covid-19 Relief Therapeutics
CONCLUSION - GAME CHANGER
Conclusion:
The rapid clinical improvement seen in these six patients treated with intravenous RLF-100 (Aviptadil), is consistent
with the finding that VIP not only blocks viral replication in the pulmonary epithelium but creates a “bystander effect”
whereby nearby monocytes secrete soluble antiviral agents to further protect ATII cells, blocks cytokine storm, and
improves oxygenation in a lung that is under attack by the SARS-CoV-2 virus. This highly specific role of VIP in the
lung may be key to combating the lethal effects of SARS-CoV-2 infection.
A randomized prospective trial is
underway, which will attempt to demonstrate that intravenous RLF-100 improves survival, oxygenation, and clinical
course of Critical COVID-19 with respiratory failure. The independent Data Monitoring Committee of that trial has
conducted the first unblinded look at the study data and identified no safety signals. Moreover, the DMC has
determined that the study is not futile in its objective to identify a statistically significant difference between aviptadil
and placebo in remission from COVID-19 respiratory failure.
The patients reported here were deemed too ill to be randomized in the ongoing phase 2/3 clinical trial of RLF-100 for
treatment of Critical COVID-19. Yet their clinical course, particularly the rapidity with which resolution in COVID
pneumonitis with improvement in oxygenation and radiographic appearance within days is highly atypical for
COVID-19 and suggests that Aviptadil has substantial potential to demonstrate clinical effectiveness in placebocontrolled trials.
Look at that we made it in the list next to the big pharma boys, very undervalued here
https://nypost.com/article/potential-covid-19-treatments/
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted By the FDA to RLF-100 (Aviptadil) For The Treatment Of Respiratory Distress In COVID-19.
https://www.businesswire.com/news/home/20200623005956/en/NeuroRx-Relief-Therapeutics-Announce-Fast-Track-Designation
$RLFTF Covid-19 Relief Therapeutics
CONCLUSION - GAME CHANGER
Conclusion:
The rapid clinical improvement seen in these six patients treated with intravenous RLF-100 (Aviptadil), is consistent
with the finding that VIP not only blocks viral replication in the pulmonary epithelium but creates a “bystander effect”
whereby nearby monocytes secrete soluble antiviral agents to further protect ATII cells, blocks cytokine storm, and
improves oxygenation in a lung that is under attack by the SARS-CoV-2 virus. This highly specific role of VIP in the
lung may be key to combating the lethal effects of SARS-CoV-2 infection.
A randomized prospective trial is
underway, which will attempt to demonstrate that intravenous RLF-100 improves survival, oxygenation, and clinical
course of Critical COVID-19 with respiratory failure. The independent Data Monitoring Committee of that trial has
conducted the first unblinded look at the study data and identified no safety signals. Moreover, the DMC has
determined that the study is not futile in its objective to identify a statistically significant difference between aviptadil
and placebo in remission from COVID-19 respiratory failure.
The patients reported here were deemed too ill to be randomized in the ongoing phase 2/3 clinical trial of RLF-100 for
treatment of Critical COVID-19. Yet their clinical course, particularly the rapidity with which resolution in COVID
pneumonitis with improvement in oxygenation and radiographic appearance within days is highly atypical for
COVID-19 and suggests that Aviptadil has substantial potential to demonstrate clinical effectiveness in placebocontrolled trials.
Look at that we made it in the list next to the big pharma boys, very undervalued here
https://nypost.com/article/potential-covid-19-treatments/
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted By the FDA to RLF-100 (Aviptadil) For The Treatment Of Respiratory Distress In COVID-19.
https://www.businesswire.com/news/home/20200623005956/en/NeuroRx-Relief-Therapeutics-Announce-Fast-Track-Designation
...settle in.. have a cookie w/some milk
$RVVTF A jump to Phase-3 is impressive in light of the steps needed...
https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/covid-19-therapeutics-general-information-interested-stakeholders
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap
...you may be sitting on a MONSTER !!! $$$ They were confident about the recoveries.. ..yep.. same fee..
must be the new breed that plays stocks like video games... 20% .. more and more are getting into strong hands.. we'll be good..
..bought some earlier one broker no problem the next wanted to charge me an extra 50 bucks foreign fee or something..
The President mentioned new Therapeutics 2-3 times yesterday with one just going into phase 3 .. maybe he'll name a few soon.. yesterday he was also focused on the storm coming up the East coast.. we'll see ..
Bam !!
$RVVTF GET A SET !! #1 Revive Therapeutics Ltd. 101,454 reads 24 hours
$LWLG We're the new kids in town.. the rookies.. we will be hazed, resented and attacked.. good thing Michael Lebby and team have hobbies that develop focus and discipline.. we're still early in the fight.. gonna take a few more beatings (jumped in) before we'll be able to really talk sh** and be taken serious.. IMO
$RVVTF Choose to invest/trade from a position of strength not (fear) weakness.
By buying this are you charged an annual fee ?
Repayment is guaranteed by the issuer – in other words, your money is only as safe as the issuer. If the issuer goes bankrupt, your ETN goes up in smoke. This additional layer of credit risk makes ETNs riskier than ETFs.
-------------------------------
Once issued, ETNs charge annual fees and trade on exchanges just like ETFs. Investors can hold their note until maturity or sell it early on the stock market.
------------------------------
But structurally, ETFs and ETNs work differently. An ETF is a fund. It owns shares of the stocks, bonds or other securities in its portfolio. When you buy an ETF, you become a fractional owner of those securities
--
About MicroSectors™ US Big Oil 3X Lvrgd ETN
The investment seeks to reflect a 3x leveraged long exposure to the performance of the Solactive MicroSectorsTM U.S. Big Oil Index on a daily basis.
The notes are senior unsecured medium-term notes issued by Bank of Montreal with a return linked to a three times leveraged participation in the performance of the index, compounded daily, less a Daily Investor Fee, the Daily Financing Charge and, if applicable, the Redemption Fee Amount.
The index is an equal-dollar weighted index designed to represent the 10 U.S. listed stocks with the largest market capitalization in the energy/oil sector.
--
What Is an ETF? The Ultimate Guide
https://money.usnews.com/investing/funds/articles/what-is-an-etf-the-ultimate-guide
..my shares were bought earlier.. I'm just talking the possible outcomes not interested in what other do with their positions.. hope you get in cheaper.. and it runs..
..he's on now.. we'll see.. ;)
Lung transplant patients have been in the news a lot lately.. if the President name drops Revive this week we'll run no matter what.. but I suspect most are in for the ride up at this point.. maybe it was Canada being offline today that added to the end of the day cash in..
President Trump will be having the Covid-19 news conference soon maybe we'll get a name drop..
..surprised by the close, maybe the 20% flippers cashed in..
$RVVTF (copy) Good post by Dave
I think everyone needs to understand what we’re essentially betting on with RVV in terms of the “covid play” (I actually entered my position as a shroom play, but now this is obviously the big focus and reason I have added many more shares)...
It all comes down to the scientific rationale about Bucillamine...
Knowing that it is very safe based on its use with arthritis in Japan is amazing, first of all. Safe drugs are good... But essentially, this is what you need to understand: NAC (a different drug) has been shown to clinically attenuate the symptoms of viral respiratory infections (like covid)...
This is primarily due to donation of Thiols... Bucillamine is 16 x more potent as a thiol donor... So based on what we know in lay terms - Bucillamine is an extremely potent and safe thiol donor, which has been shown to help lungs (in animals and humans) fight the virus.
The question is: is it potent enough to reduce hospitalizations and death on those with covid? I say yes. I base my opinion on clinical rationale aforementioned.
If successful this applies to all viral lung infections, not just covid.
85 minutes Tik Tok ... Tic Tock (English translation)
$POETF $PTK POET Technologies: Disrupting the Multi-Billion Dollar Photonics Market @BTVCeoclips https://www.b-tv.com/poet-technologies-disrupting-the-multi-billion-dollar-photonics-market-commerical-15sec/
RVVTF is hot..
..or it means you don't know what the f you are talking about ;)
$RVVTF - Excellent -
$RVVTF ALERT COVID-19 | Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3
http://thestocksmarket.net/2020/07/31/alert-covid-19-revive-therapeutics-announces-u-s-fda-approval-of-confirmatory-phase-3/
Company is into Mushroom PSILOCYBIN therapy also ...
$RVVTF ALERT COVID-19 | Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3
http://thestocksmarket.net/2020/07/31/alert-covid-19-revive-therapeutics-announces-u-s-fda-approval-of-confirmatory-phase-3/
Company is into Mushroom PSILOCYBIN therapy also ...
$RVVTF - ...we look forward to advancing Bucillamine as a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally.
https://www.streetwisereports.com/article/2020/07/01/life-sciences-firm-submits-ind-application-to-fda-for-phase-3-covid-19-study.html